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Platelets play an important role in the early
patency of lower extremity revascularization proce-
dures performed for peripheral vascular occlusive
disease.1,2 Interference with normal platelet func-
tion by use of various antiplatelet agents, such as
aspirin and ticlopidine, appears to prevent graft
thrombosis in the early postoperative period.3-12
Patients with evidence of platelet hyperactivity as
determined by relatively nonspecific tests of platelet
function, such as bleeding time and aggregation to
thrombin, have been reported to be at increased risk
for early graft thrombosis.13,14 The presence of
increased circulating von Willebrand factor has sim-
ilarly been described to increase the risk of a poor
operative outcome.15 The underlying mechanism
responsible for this platelet hyperactivity has not
been well characterized.
Thromboxane A2 (TXA2) and its precursor,
prostaglandin H2 (PGH2), are potent, ubiquitous
promoters of platelet aggregation and vascular
smooth muscle contraction that share the same
membrane receptor on the surface of platelets and
vascular smooth muscle cells.16-19 Various
TXA2/PGH2 receptor antagonists, alone and in
combination with TXA2 synthase inhibitors, have
been reported to reduce platelet deposition on the
luminal surface of implanted vascular grafts.20-23 Ilo-
prost, a synthetic prostacyclin analog with effects
that are antagonistic to those of TXA2, has also
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demonstrated the ability to increase early graft
patency.24 Because of these observations, we
hypothesized that increases in TXA2/PGH2 recep-
tor density, affinity, or both might contribute to the
increased platelet activity observed in patients who
subsequently have early graft thrombosis. This study
was undertaken to test this hypothesis.
METHODS
Patient population. Twenty-five consecutive
patients who were scheduled to undergo infrain-
guinal revascularization surgery for limb salvage at
the Medical University of South Carolina and the
Ralph Henry Johnson Department of Veterans
Affairs Medical Center were enrolled into the study.
Before initiation, the study was approved by the
Medical University of South Carolina Institutional
Review Board for Human Research. All patients
approached for enrollment consented to participate
in the study.
Experimental protocol. After obtaining
informed consent and before operation, 60 ml of
blood was collected by venipuncture for platelet
count, platelet aggregometry, and equilibrium bind-
ing studies for TXA2/PGH2 receptor activity as
described below. Clinical data retrieved included
medications, diagnosis, operation, age, sex, race,
height, weight, anesthesia type, operative time, oper-
ative blood loss, and other medical illnesses, includ-
ing renal failure. All infrapopliteal operations were
performed to the distal tibial, peroneal, or pedal ves-
sels. All patients underwent intraoperative comple-
tion angiography or on-table duplex scanning to
assess the condition of the graft. In all patients, lower
molecular weight Dextran (Rheomacrodex, Medisan
Pharmaceuticals, Parsippany, N.J.) was given intra-
venously at 20 ml/hr for 72 hours after operation.
Antiplatelet therapy, typically with aspirin, is normal-
ly given to patients who undergo lower extremity
arterial surgery, and this practice was not altered. No
patients were receiving warfarin or ticlopidine before
operation. After discharge from the hospital, patients
were seen at 1, 3, 6, and 12 months after the opera-
tion and then annually. Primary graft patency was
Fig. 1. Binding saturation isotherms of platelets derived
before operation according to subsequent graft patency
status. Open squares indicate thrombosed grafts; filled cir-
cles indicate patent grafts. Individual patient data have
been grouped according to either occluded or patent graft
status for each concentration of unlabeled ligand in this
figure for ease of illustration.
Fig. 2. Scatchard analysis of equilibrium binding data for
[125I]-BOP from platelets derived before operation. Non-
linear analysis (LIGAND program) of individual data from
patients with thrombosed grafts (open squares) yielded an
average dissociation constant (Kd) of 8.8 nmol/L and a
receptor number (Bmax) of 3100 sites/platelet, and analy-
sis of patients with patent grafts (filled circles) yielded a Kd
of 7.9 nmol/L and a receptor number (Bmax) of 1500
sites/platelet. Individual patient data have been grouped
according to either occluded or patent graft status for each
concentration of unlabeled ligand in this figure for ease of
illustration.
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determined by clinical examination and was con-
firmed by duplex ultrasound examination.
Platelet TXA2/PGH2 receptor assay. The
assay for determination of TXA2/PGH2 receptor
density has previously been described.25 Briefly,
peripheral blood was collected into syringes contain-
ing indomethacin (10 m mol/L) and ethylenedi-
amine tetraacetic acid (5 mmol/L; final concentra-
tion). Platelet pellets were obtained by differential
centrifugation, followed by resuspension in the assay
buffer of HEPES (25 mmol/L), NaCl (100
mmol/L), dextrose (5 mmol/L), and indomethacin
(10 m mol/L), pH 6.5, to approximately 5 · 108
platelets/ml. A 100 m l aliquot of resuspended
platelets was added to 0.2 nmol/L (approximately
105 cpm) of [125I]-[1S-1 a , 2 b (5Z), 3 a (1E,3S*),
4 a ]-7-[3-(3-hydroxy-4-(4 ¢ -iodophenoxy)-1-
butenyl)7-oxabicyclo-[2.2.1]heptan-2-yl]-5-hep-
tanoic acid (I-BOP) and graded concentrations of
[127I]-BOP (0.01 nmol/L to 1.0 m mol/L) to a total
volume of 200 m l. After incubation at 37° C for 30
minutes, bound ligand was separated from free li-
gand by vacuum filtration using Whatman GF/C
glass fiber filters and counted in a gamma counter
(75% efficiency for 125I). Nonspecific binding was
defined as the binding that remained in the presence
of the TXA2/PGH2 receptor antagonist L657925
(10 m mol/L; Merck Frosst, Quebec). Analysis of
equilibrium binding data consisted of Scatchard
analysis with the LIGAND program (Release 2.0,
Biosoft, Milltown, N. J.) for a one-site model. Platelet
protein was determined by the Lowry method.
Platelet aggregometry. Peripheral blood was
withdrawn into syringes containing indomethacin
(10 m mol/L) and ethylenediamine tetraacetic acid
(5 mmol/L; final concentration). The blood was
centrifuged at 175g for 20 minutes at 24° C, and the
resulting platelet-rich plasma was pipetted off and
placed into polyurethane centrifuge tubes. The
platelet-rich plasma was centrifuged at 800g for 20
minutes at 24° C, and the platelet pellet was resus-
pended in Tris-buffer (Tris-HCl [50 mmol/L],
NaCl [100 mmol/L], dextrose [5 mmol/L], and
indomethacin [10 m mol/L], pH 7.4) to a concen-
tration of approximately 2.5 · 108 platelets/ml.
Before aggregation, CaCl2 was added to the washed
platelets (final concentration, 250 m mol/L). Platelet
aggregation was performed in a Chronolog model
300 aggregometer (Chronolog, Havertown, Pa.).
Washed platelets (450 ml) were added to individual
silanized glass cuvettes. The TXA2 mimetic U46619
(Upjohn, Kalamazoo, Mich.) was added in final con-
Fig. 3. Combined concentration-response curves for
aggregation induced by U46619. Open squares indicate
thrombosed grafts; filled circles indicate patent grafts.
Error bars represent standard error. Individual patient data
have been grouped according to either occluded or patent
graft status for each concentration of unlabeled ligand in
this figure for ease of illustration.
Fig. 4. Correlation of platelet density (Bmax) with maxi-
mal slope (Vmax) of platelet aggregation to 5 m mol/L
U46619. Open squares indicate thrombosed grafts; filled
circles indicate patent grafts. Each data point represents an
individual patient (r = 0.36; p < 0.01).
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centrations of 20 nmol/L to 5 m mol/L. The aggre-
gation response was observed for 2 minutes and was
expressed as a percentage of the maximal response
observed to collagen (1 m g/ml). Dose-response
curves were constructed for U46619. The EC50 val-
ues, defined as the concentration required to pro-
duce 50% of the maximum aggregation response
within 1 minute, were derived from the dose-
response curves. Maximal velocity of aggregation
(Vmax) was defined as the initial slope of the aggre-
gation response to 5 m mol/L U46619.
Data management. Statistical analysis for indi-
vidual patient measurements consisted of two-tailed,
unpaired Student’s t test, Fisher’s exact test, and the
c
2 test where appropriate. A p level less than 0.05
Fig. 5. Distribution of receptor density (Bmax) according
to study group.
was considered significant to reject the null hypoth-
esis. All values in the text are expressed as mean ±
SD.
RESULTS
Twenty-five patients were enrolled in the study.
Five of the 25 patients (20%) had occlusion of their
graft within the first 3 months. All five occluded
grafts were comprised of autogenous vein. Four
expanded polytetrafluoroethylene grafts and 16
autogenous vein grafts remained patent during the
first 3 months. A missed valve was the cause for graft
occlusion in one patient. In the other patients, no
cause for occlusion could be definitively identified.
Preoperative patient demographic and risk factors
are presented in Table I according to graft patency
status and in Table II according to TXA2/PGH2
receptor density.
The specific binding of [125I]-BOP was signifi-
cantly greater before operation in the platelets of
patients who subsequently had graft thrombosis
(Fig. 1). Preoperative platelet TXA2/PGH2 receptor
density was significantly higher in the five patients
who had graft thrombosis within 3 months of oper-
ation (Bmax [platelet mass], 2.6 ± 1.0 pmol/mg pro-
tein vs 1.3 ± 0.9 pmol/mg protein, p = 0.001; Bmax
[platelet number], 3100 ± 1300 vs 1500 ± 1100
Table I. Demographic and preoperative risk factors
of patients with thrombosed and occluded grafts at
3 months
Thrombosed (%) Patent (%)
n=5 n=20
Mean age (range) 68 yr (51 to 75) 69 yr (54 to 88)
Male/female 5/0 (100/0) 12/8 (60/40)
Black/white 3/2 (60/40) 13/7 (65/35)
Diabetes/no diabetes 5/0 (100/0) 13/7 (65/35)
Preoperative ASA/no ASA 3/2 (60/40) 12/8 (60/40)
Tissue loss/rest pain 4/1 (80/20) 15/5 (75/25)
Vein conduit/ePTFE 4/1 (80/20) 16/4 (80/20)
Popliteal/infrapopliteal 1/4 (20/80) 6/14 (30/70)
NS, Not significant; ASA, acetylsalicylic acid (aspirin); ePTFE,
expanded polytetrafluoroethylene. Popliteal/infrapopliteal indi-
cates distal anastomosis target vessel.
Fig. 6. Life table analysis of cumulative primary graft
patency data for patients according to TXA2/PGH2
receptor density >3000 sites/platelet (open squares; n = 5)
or <3000 sites/platelet (filled circles; n = 20). Error bars
represent standard error. Z (Yates correction) = 2.97; p <
0.005 between groups.
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sites/platelet, p = 0.004). A single I-BOP binding
site was observed in the platelets of all patients (Fig.
2). No significant differences in TXA2/PGH2 recep-
tor affinity for I-BOP (Kd 8.8 ± 3.6 nmol/L vs 7.9
± 4.5 nmol/L; p > 0.05) or platelet number
(320,000 ± 190,000/min3 vs 300,000 ±
80,000/mm3; p > 0.05) were noted between
groups.
Aggregometry revealed that the EC50 for U46619
was lower (26 ± 6 nmol/L vs 57 ± 30 nmol/L; p <
0.05) in patients with early thrombosis, indicating
functionally increased sensitivity to TXA2 mimetics
(Fig. 3). Differences in Vmax between patients with
occluded and patent grafts did not attain statistical sig-
nificance (16 ± 6 vs 12 ± 4; p = 0.12), although the
power to detect a 25% difference in this measurement
was less than 0.50, allowing the possibility of a type II
statistical error. Platelet receptor density (Bmax) did
correlate with Vmax (r = 0.36; Fig. 4).
Early graft thrombosis was more likely in patients
with a platelet TXA2/PGH2 receptor density greater
than 3000 sites per platelet (odds ratio, 76; 95% con-
fidence interval, 3.9 to 1500; Fig. 5). Life table analy-
sis of patients grouped according to a preoperative
Bmax threshold of greater than 3000 sites per platelet
confirmed the primary patency rate to be significantly
worse in this group (p < 0.005; Fig. 6; Appendix A).
Early graft thrombosis was also more likely in patients
with an EC50 for U46619 less than 30 nmol/L (odds
ratio, 16; 95% confidence interval, 1.4 to 180; Fig. 7).
These early differences in the patency rate were not
sustained and did not reach statistical significance by
life table analysis (Fig. 8; Appendix B). The potential
value of Bmax and EC50 as preoperative predictors of
graft occlusion is illustrated in Table III.
Preoperative use of aspirin did correlate with
platelet aggregation to U46619 (EC50, 40 ± 19
nmol/L with aspirin vs 68 ± 35 nmol/L without
aspirin; p = 0.02) but not platelet TXA2/PGH2 recep-
tor density (Bmax, 1600 ± 1000 sites per platelet with
aspirin vs 1500 sites per platelet without aspirin; p >
0.05) or graft patency (80% for both groups). No cor-
relations were observed between diabetes mellitus and
platelet TXA2/PGH2 receptor density (Bmax, 1900 ±
1400 sites per platelet with diabetes vs 1700 ± 900
sites per platelet without diabetes; p > 0.05), platelet
aggregation (EC50, 52 ± 31 nmol/L with diabetes vs
48 ± 27 nmol/L without diabetes; p > 0.05), or graft
patency rate (13 of 18 [72%] with diabetes vs 7 of 7
[100%] without diabetes; p > 0.05).
DISCUSSION
This study has detected an increase in sensitivity
to TXA2 in the platelets of patients who subse-
quently have graft thrombosis early after lower
extremity bypass surgery. This heightened sensitivity
appears to result from increased expression of
TXA2/PGH2 receptors on the platelet surface.
These findings support earlier reports of increased
Fig. 7. Distribution of platelet EC50 according to study
group. Fig. 8. Life table analysis of cumulative primary graft
patency data for patients according to EC50 for platelet
aggregation to U46619 <30 nmol/L (open squares; n = 8)
or >30 nmol/L (filled circles; n = 17). Error bars represent
standard error. Z (Yates correction) = 1.10; p = NS
between groups.
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platelet activity in patients who are prone to graft
thrombosis.13,14 Platelet aggregometry to adenosine
diphosphate, a weak platelet agonist, has been stud-
ied as a predictor of failure for knitted Dacron
femoropopliteal grafts in human patients.13 An
aggregation score was derived from a combination
of the magnitude of the initial reversible wave of
aggregation, the overall magnitude of the second
wave of irreversible aggregation, and the patient’s
platelet count. This complex scoring system was able
to identify a subgroup of patients with increased
platelet aggregability who subsequently had an
extremely high rate of graft failure. Aggregation to
thromboxane A2 was not evaluated in that study.
Bleeding time as a measure of in vivo platelet
function has been reported to accurately predict
subsequent graft occlusion in patients who undergo
femoropopliteal bypass grafting with polytetrafluo-
roethylene grafts.14 Six grafts that were patent
longer than 5 years were associated with a bleeding
time of at least 6.5 minutes, whereas none of the six
patients whose grafts occluded within 6 months of
implantation had bleeding times longer than 5.5
minutes. Other parameters of coagulation, including
prothrombin time and partial thromboplastin time,
were not associated with the graft patency rate. As
we also observed, this predictive ability was inde-
pendent of the concomitant use of aspirin. It may at
first seem surprising that the increases in platelet
sensitivity as a result of TXA2/PGH2 receptor den-
sity might occur as a result of concurrent aspirin use.
Although this has not yet been observed in humans,
aspirin does appear to increase TXA2/PGH2 recep-
tor density in a porcine model of carotid bypass.26
The mechanism for this effect would presumably
relate to upregulation of TXA2/PGH2 receptors as a
result of a chronic suppression of the TXA2 ligand.
Response to platelet aggregometry has long
been recognized as a predictor of graft patency in a
canine model, with nonaggregators much more like-
ly to enjoy long-term graft patency.27,28 It has been
conjectured that the superior predictive value of
arachidonic acid–induced aggregation compared
with adenosine diphosphate might indicate a differ-
ence in sensitivity of the receptor to TXA2. Such a
theory is further supported by the failure to detect
concomitant increases in TXB2, the stable metabo-
lite of TXA2, which would imply that no additional
TXA2 is necessary in the presence of increased
platelet TXA2/PGH2 receptor density.29
Instead of assuming that increases in
TXA2/PGH2 receptor density before graft implan-
tation may predispose patients to early graft throm-
bosis, it is equally possible that such changes are
merely indicative of more advanced systemic disease.
It has been observed that patients with acute
myocardial infarction, presumably associated with
coronary thrombosis, also exhibit increased platelet
TXA2/PGH2 receptor density compared with
patients with unstable angina or with noncoronary
causes for chest pain.30 It is intriguing that once
these patients began to convalesce from their
myocardial infarctions, the Bmax of their platelets
returned toward normal regardless of aspirin thera-
py, suggesting that the original cause might involve
a stress response. It is unfortunate that convalescent
samples were not available in the present study for
comparison to see whether this phenomenon occurs
with peripheral vascular reconstruction, as well.
Despite these observations, the actual mecha-
nism for the observed changes in platelet receptor
density remains unclear. One explanation that has
been offered is that a greater proportion of the
platelets are younger and larger in patients with
advanced atherosclerotic disease because of
increased platelet turnover.30-34 Such presenescent
platelets might be expected to demonstrate a greater
Table II. Demographic and preoperative risk fac-
tors of patients according to TXA2/PGH2 receptor
density
Bmax > 3000 Bmax < 3000 
sites/platelet sites/platelet
n=5 n=20
Mean age (range) 67 yr (51 to 75) 69 yr (54 to 88)
Male/female 5/0 (100/0) 12/8 (60/40)
Black/white 3/2 (60/40) 13/7 (65/35)
Diabetes/no diabetes 5/0 (100/0) 13/7 (65/35)
Preoperative ASA/no ASA 2/3 (40/60) 13/7 (65/35)
Tissue loss/rest pain 4/1 (80/20) 15/5 (75/25)
Vein conduit/ePTFE 4/1 (80/20) 16/4 (80/20)
Popliteal/infrapopliteal 1/4 (20/80) 6/14 (30/70)
NS, Not significant; ASA, acetylsalicylic acid (aspirin); ePTFE,
expanded polytetrafluoroethylene. Popliteal/infrapopliteal indi-
cates distal anastomosis target vessel.
Table III. Value of TXA2/PGH2 receptor density
(Bmax) and sensitivity of platelet aggregation to
TXA2 mimetics (EC50) for predicting early graft
occlusion
Bmax EC50
>  3000 sites/platelet    <  30 nmol/L
Sensitivity 0.8 0.8
Specificity 0.95 0.8
Likelihood ratio positive 16.0 4.0
Likelihood ratio negative 0.21 0.25
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TXA2/PGH2 receptor density. Others have
observed a decrease in the density of platelet prosta-
cyclin receptors35 and an increase in the affinity and
density of a 2-adrenergic receptors in patients with
advanced atherosclerotic disease, which might syner-
gistically lead to platelet hypersensitivity to TXA2.36
Certainly, increased platelet sensitivity to TXA2
would seem to be particularly hazardous immediate-
ly after bypass surgery. Locally increased TXB2 pro-
duction has been detected after arterial bypass graft-
ing.37-40 The luminal surface of a normal upstream
artery spontaneously secretes both prostacyclin and
TXA2, whereas the arterial wall distal to a prosthetic
graft may produce increased levels of these
prostanoids with an overabundance of TXA2 relative
to prostacyclin substances at different proportions.
Even gentle use of a valvulotome during in situ
autogenous vein bypass grafting appears to provoke
increased platelet release of TXA2.41
Although patients with diabetes are known to
experience increased platelet turnover, enhanced
sensitivity to various aggregating agents, and
increased platelet TXA2 production,30,42 this group
of patients was not excluded from the study. In fact,
reflecting the risk factors of patients who are typical-
ly treated at the authors’ institutions, the vast major-
ity of patients had diabetes. No significant difference
in the incidence of diabetes was observed between
the two groups (Table I), and the presence of dia-
betes did not correlate with any of the other mea-
sured factors. It is possible that the effect of diabetes
on graft patency rates or TXA2/PGH2 receptor den-
sity may have been missed because of the small sam-
ple size. To prove that the observed differences in
graft patency rates and TXA2/PGH2 receptor densi-
ty were statistically significant, a total of 38 and 376
patients, respectively, would have been required,
assuming an alpha error of 0.05 and a power of 0.80.
Elevated platelet TXA2 receptor levels and
enhanced sensitivity of platelet aggregation to TXA2
appear to predict early arterial graft thrombosis inde-
pendent of aspirin use. This preliminary study com-
prised only 25 patients, so that a number of possi-
bilities for the introduction of a type II error exist.
Clinical use of TXA2/PGH2 receptor density to pre-
dict early graft thrombosis must await larger, more
comprehensive studies, including independent con-
firmation of our results. However, although many of
the implications of our observations remain to be
investigated, they would appear to suggest an advan-
tage for the use of specific TXA2/PGH2 receptor
antagonism to prevent one of the mechanisms that
contributes to early graft occlusion.
We gratefully acknowledge the guidance and inspira-
tion provided by Perry V. Halushka, MD, PhD.
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APPENDIX A. Life table analysis of cumulative primary graft patency data according to TXA2/PGH2
receptor density
Interval No. of grafts No. of grafts No. of grafts Interval patency Cumulative Standard 
end (mo) at risk failed withdrawn rate (%) patency rate (%) error (%)
Bmax > 3000 sites/platelet
0-2 5 4 0 20 20 18
2-4 1 0 0 100 20 18
4-6 1 0 0 100 20 18
6-8 1 0 0 100 20 18
8-10 1 0 0 100 20 18
10-12 1 0 0 100 20 18
12-14 1 0 1 100 20 18
Bmax < 3000 sites/platelet
0-2 20 1 0 95 95 5
2-4 19 0 1 100 95 5
4-6 18 0 0 100 95 5
6-8 18 2 0 89 84 8
8-10 16 0 0 100 84 8
10-12 16 1 0 94 79 9
12-14 15 1 4 93 74 10
14-16 10 0 3 100 74 10
16-18 7 0 1 100 74 10
18-20 6 1 1 83 62 14
20-22 4 0 1 100 62 14
22-24 3 0 0 100 62 14
APPENDIX B. Life table analysis of cumulative primary graft patency data according to EC50 for platelet
aggregation to U46619
Interval No. of grafts No. of grafts No. of grafts Interval patency Cumulative Standard 
end (mo) at risk failed withdrawn rate (%) patency rate (%) error
EC50 < 30 nmol/L
0-2 8 4 0 50 50 18
2-4 4 0 0 100 50 18
4-6 4 0 0 100 50 18
6-8 4 0 0 100 50 18
8-10 4 0 0 100 50 18
10-12 4 0 0 100 50 18
12-14 4 0 0 100 50 18
14-16 4 0 0 100 50 18
16-18 4 0 1 100 50 18
18-20 3 1 0 67 33 18
20-22 2 0 0 100 33 18
22-24 2 0 0 100 33 18
EC50 > 30 nmol/L
0-2 17 1 0 94 94 6
2-4 16 0 1 100 94 6
4-6 15 0 0 100 94 6
6-8 15 2 0 87 82 10
8-10 13 0 0 100 82 10
10-12 13 1 0 92 75 11
12-14 12 1 5 92 69 12
14-16 6 0 3 100 69 12
16-18 3 0 0 100 69 12
18-20 3 0 1 100 69 12
20-22 2 0 1 100 69 12
22-24 1 0 0 100 69 12
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Dr. William C. Krupski (Denver, Colo.). First, I
would like to compliment Dr. Brothers and his associates
for a nicely performed study and an excellent presentation
this morning. The authors have shown increased throm-
boxane receptor density in the platelets of patients whose
graft thrombosed within 3 months of undergoing bypass
grafting. Early graft thromboses were more likely to occur
in patients with thromboxane receptor density greater
than 3000 sites per platelet. In addition, platelets from
patients who had early graft occlusion required less throm-
boxane mimetic to aggregate. Thus patients with early
graft occlusion presumably have enhanced sensitivity to
thromboxane.
Vascular surgeons have often said in jest—or occasion-
ally truly believed—that all of their graft occlusions
occurred in patients with hypercoagulable states. Dr.
Brothers’ presentation would lend support to this con-
tention. I wish it were so simple.
Four years ago at these meetings, Dr. Mills and col-
leagues described serial duplex surveillance in 227 consec-
utive infrainguinal bypass grafts. Of note, only 8% of the
grafts thrombosed in the 5-year follow-up period, in con-
trast to a 20% 3-month thrombosis rate in the current
study. Technical problems were far and away the most
common cause of failed or failing grafts. In the Mills study,
corroborating data were reported from groups from
Northwestern and the New England Medical Center. In
the Mills report, only 4.3% of failures were attributed to
hypercoagulable states, a far cry from the 100% described
this morning. Although I applaud the authors for their
honesty in reporting this high early failure rate, how do
they justify a 20% 3-month occlusion rate when others
report 3% to 5%? Did the authors use intraoperative
angioscopy, duplex ultrasound, or arteriography to rule
out technical or anatomic problems that might explain
early graft thromboses? What was the postoperative sur-
veillance protocol?
A second concern I have with the manuscript relates to
hematologic considerations. It is clear that absolute
platelet counts play an important role in thromboembolic
events such as graft occlusions. The authors at the very
least must provide data regarding platelet counts in
patients who had early graft occlusion versus those with
early patency. Do you have any in vitro data investigating
the other two pathways for platelet aggregation, namely
thrombin and ADP-mediated aggregation?
Although aspirin treatment reportedly conferred no
protection from thrombosis, it would be important to
determine compliance by measuring salicylate levels. I am
also concerned that the relatively small number of patients
in this study may produce a type II statistical error with
respect to the efficacy of aspirin treatment.
Finally, because this is, in a sense, a study of hyperco-
agulability, did the authors measure other factors that con-
tribute to thrombosis, such as antithrombin III, protein
C, protein S, or factor V (Leiden)?
Several additional factors warrant analysis by the
authors. I would be interested to know the correlation
with graft thrombosis of at least the following variables:
active cigarette smoking, concomitant procedures that
may have contributed to the complexity of the case, the
target vessels for bypass grafting, and more detailed infor-
mation regarding runoff.
In summary, the study reported this morning does
have great potential, particularly if specific thromboxane
receptor inhibitors are developed and are shown to pre-
vent early graft thrombosis. However, despite our desire
to blame platelets for our graft thromboses, I fear we must
continue to accept responsibility and attribute most fail-
ures to technical problems.
Dr. Thomas E. Brothers. Thank you, Dr. Krupski. I
very much appreciate your initial gracious comments fol-
lowed by your pointed yet insightful criticism. I would like
to emphasize that the overall purpose of this study and our
presentation is not to blame hypercoagulable states for our
failures, nor is it necessarily to report to you our overall
experience with lower extremity bypass grafting, but
rather to describe our attempts to elicit the nature of the
platelet hyperactivity that has been described by others.
However, since the point is raised, I am forced to respond
to it. In fact, I would agree that the 20% early thrombosis
rate is quite high. However, it is a very small sample that
does not really accurately reflect our overall experience,
which, as has previously been published, is much closer to
10% or below.
When we actually went back and looked at the results
of why these grafts thrombosed, we could only identify
one out of the five occlusions as being a truly technical
error, and the rest were of uncertain cause. This observa-
tion mirrors our overall experience that in many of these
patients we cannot quite find out the cause for the failure
despite aggressive searching.
In terms of completion studies, practices varied among
the members of our group, but all of the patients in this
study did undergo completion angiography or on-table
duplex scanning. We certainly agree with that practice as
well as the concept of postoperative surveillance. Our
postoperative surveillance protocol involves getting a
study at 3 weeks, 3 months, 6 months, and 12 months
during the first year after bypass grafting.
I would agree very much that it is important to
include the platelet numbers, and I will certainly add
platelet numbers to the manuscript. But for the moment
you’re just going to have to take my word for it that there
were no differences in the mean and a range of the platelet
numbers between the patient groups.
We did not investigate the activity of the GP IIb/IIIa
receptors, nor did we duplicate the studies of the group
DISCUSSION
JOURNAL OF VASCULAR SURGERY
Volume 27, Number 2 Brothers et al. 327
from Seattle in looking at the response to ADP. Although
certainly from a mechanistic standpoint it occurs to me
that either the change in thromboxane density may either
be somewhat supplemental to the increased aggregation
to ADP or that there are other things going on that affect
both of these findings at the same time. I am not prepared
to invoke thromboxane receptor activity as the sole cause
of the platelet hyperactivity.
You certainly make a very important point regarding
the compliance with aspirin. We were not wise enough to
think to measure salicylate levels. I will say that all patients
did receive aspirin after operation, and, at least while they
were in the hospital, that could be monitored.
Because of our previous work and interest, this study
was focused on the involvement of the platelet and the
thromboxane receptor, not on the presence or absence of
hypercoagulable states, and we do not routinely check for
those conditions in all of our patients. Certainly the pres-
ence of a hypercoagulable state is greater in patients with
early disease, especially among younger patients, as has
been well described by our colleagues in Columbia, South
Carolina. Neither the thromboxane density nor the graft
patency data correlated with active tobacco use, concomi-
tant operations, the target vessel, or the arterial runoff.
In summary, I would agree absolutely that we do need
to accept responsibility for our failures and not try to pass
them off as something out of our control. However, it is
hard for me to see how a technical failure that occurs, such
as a missed valve, could be predicted by a preoperative ele-
vation in thromboxane receptor density. And I would cer-
tainly point out, in fact, that these elevations were associ-
ated with our subsequent results and that we obviously
have quite a bit of work ahead of us trying to sort this out
further.
Dr. William M. Abbott (Boston, Mass.). We hear
about test after test after test looking for the hypercoagu-
lable state, and we are continuously left with results and
confounded about what we are supposed to do about
them. This adds a lot of time and expense. I am curious
from a practical standpoint how difficult this test is to per-
form. Can it be done in the operating room, for example?
How expensive would it be?
Dr. Brothers. These tests are not for routine clinical
use. They are quite expensive. They require at least 8 hours
of time. Again, these assays are not intended as routine pre-
operative screening tests. They are receptor-ligand assays
and can be somewhat difficult to do. This is not something
that I personally see as something that we should expect to
use in the near future, nor would I recommend doing so
on the basis of these preliminary studies.
Dr. Richard J. Fowl (Scottsdale, Ariz.). I was in
Cincinnati, and you referred to our study there, so I rise
to support some of your conclusions. The platelets, I
think, are probably a very important parameter in causing
occlusion, and yet it’s a very difficult thing to prove. In
response to one of Dr. Krupski’s comments, we limited
our study to polytetrafluoroethylene only. And we did per-
form all the coagulation parameter assays, including pro-
tein S, protein C, antithrombin III, a fibrinolytic profile,
and D-dimers, and just about anything else you could
think of. However, factor V (Leiden) assay wasn’t available
at the time.
We compared two groups of people. One group of
people had 5-year patency with polytetrafluoroethylene
and no problems, and the grafts in the other occluded
within 6 months. The only thing that was different was the
bleeding time, and it was markedly short, although all of
the patients were taking aspirin. I think that one of the
conclusions I’m coming to from your work as well as our
own is that aspirin is probably not such a good antiplatelet
agent in many people. When I visited his laboratory in
Seattle several years ago, Dr. Sauvage observed, and this
isn’t published anywhere, that he found that about half his
population does not respond to aspirin therapy as an
antiplatelet agent. So I wonder whether you have thought
about trying any other antiplatelet agents and rechecking
your thromboxane assays? I think that might be a good
thing to try, using perhaps dipyridamole or even ibupro-
fen or any of the other agents that are known to be
antiplatelet agents.
Dr. Brothers. I appreciate the comments. We actual-
ly have not specifically done that at this time. In an animal
model that was previously presented, however, we looked
at the results of chronic aspirin use or chronic use of a
thromboxane receptor antagonist and actually found, at
least in the porcine model, that chronic use of one of these
agents is actually associated with an increase in the densi-
ty. So as you might expect, if there is less of the ligand
around, one of the ways that the cell responds is to
increase expression of the receptor. From a functional
standpoint, I’m not entirely sure what this all means, but
we have not actually looked at other antiplatelet agents at
this point.
Dr. Michael Sobel (Richmond, Va.). I compliment
you on a very elegant scientific study and would just like
to focus my question on the question of chicken versus
egg. And this is a real problem with all of the studies we
perform regarding platelets, that is, when platelets are acti-
vated for any reason their receptors are upregulated.
Because what you and all of us may be looking at is a
symptom or manifestation of a state of activated platelets,
it really doesn’t get to the issue of causation. So that while
inhibition or blockade of thromboxane receptors might be
effective, it also might be just treating the symptom rather
than getting to the issue of why certain patients have acti-
vated platelets in their circulation.
Dr. Brothers. I couldn’t agree with you more. And
again, I’m not claiming to prove that there is a cause and
effect relationship here. Certainly, in the other study
from our institution, the suggestion was that either the
presence of increased stress associated with chest pain
and hemodynamic instability might perhaps contribute
to the increase in receptor density or perhaps just that
that was a marker of more diffuse atherosclerotic disease.
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As a way to kind of check that in our group of patients,
we thought that if there was an increase in either gangrene
or ongoing ulceration or pain in the extremities, such
stressful situations might be associated with increased den-
sity. It turned out not to be the case. Also, trying to look
at the degree of outflow or the overall condition of the
outflow as an indicator of the extent of atherosclerosis,
also did not seem to correlate. But I agree, we have
reported an association. At this point, I would not say that
this represents a cause and effect.
Dr. Robert W. Hopkins (Providence, R.I.). I
enjoyed the paper very much, but I do have a question
about your rejection of the hypothesis that diabetes might
be related to this. If I understand your data correctly, all
of the patients whose grafts occluded had diabetes. There
are a lot of patients with diabetes in the study group, and
in the nonoccluded group about two thirds had diabetes.
But not all diabetes is the same. I have two questions for
you. First, was there a difference in the characteristics of
the diabetes between the occluded and nonoccluded
groups? Second, in the previous study with coronary dis-
ease, was there any particular relationship between the
patients with diabetes and those without diabetes?
Dr. Brothers. You are very perceptive. In fact, more
than 70% of our patients overall have diabetes. That’s just
the population that we see. Those differences were not
significant. Perhaps that’s a type II error, perhaps not.
Whether it was type I or type II diabetes did not seem to
correlate. I will say that the same group at our institution
that published the previous results looking at coronary
disease actually looked at the expression of the receptor in
patients with diabetes, and in fact there is increased recep-
tor density in patients with type I diabetes. This is proba-
bly related to some degree to the fact that patients with
type I diabetes are known to have larger platelets and per-
haps that in some way allows for more receptors to be pre-
sent. We actually have an active proposal to try to corre-
late the degree of thromboxane receptor density in
patients with type I diabetes with subsequent progression
of atherosclerotic or lower extremity arteriosclerotic dis-
ease.
Dr. Edmund J. Harris, Jr. (Stanford, Calif.). Did you
repeat the thromboxane assay at the time of the first graft
thrombosis and also at your first follow-up with the patent
grafts? From what I understand from your presentation,
you did the thromboxane assay only once before opera-
tion. How do we know that that value is valid in the peri-
operative period when you’re observing the grafts failing?
Dr. Brothers. These assays were all performed before
the patient was anesthetized, before they had any interven-
tion, usually the day before operation. Sadly, we did not get
follow-up studies to look at, especially in light of the data
with coronary disease that suggested that once the acute
myocardial infarction was over then the receptor density
went back to normal. That is definitely something we ought
to do, but unfortunately we don’t have those data.
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